1. Home
  2. PRG vs MESO Comparison

PRG vs MESO Comparison

Compare PRG & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRG
  • MESO
  • Stock Information
  • Founded
  • PRG 2020
  • MESO 2004
  • Country
  • PRG United States
  • MESO Australia
  • Employees
  • PRG N/A
  • MESO N/A
  • Industry
  • PRG Diversified Commercial Services
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PRG Consumer Discretionary
  • MESO Health Care
  • Exchange
  • PRG Nasdaq
  • MESO Nasdaq
  • Market Cap
  • PRG 1.4B
  • MESO 1.3B
  • IPO Year
  • PRG N/A
  • MESO N/A
  • Fundamental
  • Price
  • PRG $35.53
  • MESO $15.46
  • Analyst Decision
  • PRG Hold
  • MESO Buy
  • Analyst Count
  • PRG 5
  • MESO 3
  • Target Price
  • PRG $37.20
  • MESO $18.00
  • AVG Volume (30 Days)
  • PRG 302.1K
  • MESO 223.6K
  • Earning Date
  • PRG 10-22-2025
  • MESO 08-28-2025
  • Dividend Yield
  • PRG 1.46%
  • MESO N/A
  • EPS Growth
  • PRG 109.72
  • MESO N/A
  • EPS
  • PRG 5.11
  • MESO N/A
  • Revenue
  • PRG $2,518,216,000.00
  • MESO $17,198,000.00
  • Revenue This Year
  • PRG $1.44
  • MESO $293.59
  • Revenue Next Year
  • PRG $3.56
  • MESO $218.64
  • P/E Ratio
  • PRG $6.96
  • MESO N/A
  • Revenue Growth
  • PRG 5.17
  • MESO 191.39
  • 52 Week Low
  • PRG $23.50
  • MESO $6.00
  • 52 Week High
  • PRG $50.28
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • PRG 60.92
  • MESO 54.99
  • Support Level
  • PRG $34.45
  • MESO $14.67
  • Resistance Level
  • PRG $36.43
  • MESO $15.67
  • Average True Range (ATR)
  • PRG 0.78
  • MESO 0.45
  • MACD
  • PRG -0.07
  • MESO 0.03
  • Stochastic Oscillator
  • PRG 56.94
  • MESO 77.56

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: